Novartis Ag (NVSEF) Change in Cash (2009 - 2025)

Novartis Ag has disclosed Change in Cash across 14 years of filings, most recently posting -$792.0 million for Q2 2025.

• Change in Cash for Q2 2025 came in at -$792.0 million, up 48.3% year-over-year; the trailing twelve-month figure through Jun 2025 was -$2.1 billion (up 80.96% YoY), and the FY2025 annual result was -$600.0 million, up 68.98% from the prior year.
• Change in Cash came in at -$792.0 million for Q2 2025 at Novartis Ag, up from -$5.3 billion in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $5.5 billion in Q3 2024 to a low of -$10.2 billion in Q2 2022.
• The 5-year median for Change in Cash is -$1.3 billion (2023), against an average of -$2.5 billion.
• Across the five-year window, Change in Cash surged 102.07% in 2023 and slumped 3061.11% in 2024, its largest moves.
• Novartis Ag's Change in Cash stood at -$4.3 billion in 2021, then plunged by 100.21% to -$8.7 billion in 2022, then soared by 102.07% to $180.0 million in 2023, then plunged by 3061.11% to -$5.3 billion in 2024, then surged by 85.14% to -$792.0 million in 2025.
• The last three Change in Cash figures came in at -$792.0 million (Q2 2025), -$5.3 billion (Q4 2024), and $5.5 billion (Q3 2024), per Business Quant data.